THE INFLUENCE OF ANTIDIABETIC COMBINED MEDICINAL PRODUCT GLIK VERIN BASED ON VOGLIBOSE AND QUERCETIN ON LIPID E XCHANGE INDICES UNDER CONDITIONS OF EXPERIMENTAL METABOLIC SYNDROME

Authors

  • Kononenko N. M. National University of Pharmacy, Kharkov, Ukraine
  • Ruban O. A. National University of Pharmacy, Kharkov, Ukraine
  • Chikitkina V. V. National University of Pharmacy, Kharkov, Ukraine
  • Kovalevska I. V. National University of Pharmacy, Kharkov, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2020.4.16

Keywords:

glikverin, quercetin, voglibose, metabolic syndrome, lipid metabolism

Abstract

The aim of this work was to study the effect of glikverin based on voglibose and quercetin on lipid metabolism in experimental metabolic syndrome. Materials. The metabolic syndrome model was reproduced by keeping rats on a hypercaloric diet (containing 20 % fatty food and fructose ad libitum (1 g per day per 100 g of body weight as a 10 % aqueous solution) for 8 weeks. The content of complex carbohydrates in the daily diet of animals was 60 %. The following groups of rats were used: group 1 — intact control; group 2 — rats receiving a hypercaloric diet; group 3 — animals that were administered glikverin at a dose of 50 mg/kg on the background of hypercaloric diet, groups 4–6 — animals that were administered comparison drugs on the background of hypercalorie diet: quercetin substance at a dose of 50 mg/kg, the voglibose substance at a dose of 0.06 mg/kg and standard drug — metformin at a dose of 60 mg/kg. The study drugs were administered simultaneously with the hypercaloric diet intragastrically for 8 weeks. Lipid metabolism was assessed by body weight gain, total cholesterol, triacylglycerols, low- and highdensity lipoprotein cholesterol, and serum TNF-α levels. Results. It was found that the combined product glikverin reduces body weight gain by 66%, which is probably specified by the action of its component component voglibose, which slows down the breakdown and absorption of carbohydrates in the intestine. The results of the study of lipid metabolism in blood serum showed that the combination of voglibose and quercetin in the combined agent leads to the summation of their pharmacological effects. Under the influence of glikverin, the content of total cholesterol decreased by 1.7 times, LDL-C and TAG - by 1.6 and 2.2 times, respectively, the level of HDL-C increased by 46%. Comparative analysis showed that the pronounced antiatherogenic effect of the combined agent is due to the effect of both components, with a predominant effect on the lipid metabolism of quercetin. The revealed hypocholesterolemic and hypolipidemic action provide an antiatherogenic effect. The severity of this effect, which provided glikverin, significantly exceeded the comparison agents quercetin, voglibose and metformin. The combination of voglibose and quercetin also reduced by 38% the content of TNF-α - an inductor of insulin resistance in obesity. The obtained results substantiate the expediency of further pharmacological study of the antidiabetic properties of glikverin as a promising tool for the treatment of metabolic syndrome and type 2 diabetes.

References

International diabetes federation Diabetes Atlas —8th edition, available at: http://www.diabetesatlas.org.

Tsytovskyi MN. Nauk visn Uzhhorodskoho un-tu 2017;55(1): 168-177.

Kobyliak NM, Kyriienko DV. Mezhdunar Endokrynol Zhur 2015; 1(65): 73-84.

Lorenzati B, Zucco C, Miglietta S, et al. Pharmaceuticals 2010; 3(9): 3005-3020.

Markhon NO, Mamchur VY, Zhyliuk VI, Lievykh AE. Visn Probl Biol Med 2015; 1(117): 156-162.

Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL.Ther Adv Cardiovasc Dis 2017; 11(8): 215-225.

Bluher M. Nat Rev Endocrinol 2019; 15(5): 288-298.

Atawia RT, Bunch KL, Toque HA, et al. Front Biosci (Landmark Ed) 2019; 24: 890-934.

Sokolova LK. Mizhnar Endokrynol Zhurn 2018;14(1): 71-75.

Zhou J, Massey S, Story D, Li L. Int J Mol Sci 2018;19(10): 2863.

Drapkyna OM, Hehenava BB. Klynytsyst 2018; 12(1): 29-35.

Horbenko NI, Borikov OYu, Ivanova OV, et al. Ukr Biochem J 2019; 91(5): 46-54.

Horbenko NI, Ivanova OV, Borikov АYu. Probl Endokryn Patolohii 2016; 3(57): 91-99.

Pankiv VI, Cherniavska IV. Mizhnar Endokrynol Zhurn 2014; 7: 45-49.

Zhuravlova LV, Pylov DI. Probl Endokryn Patolohii 2019; 3: 113-117.

Downloads

Published

2021-06-30

How to Cite

Kononenko , N. M., Ruban , O. A., Chikitkina , V. V., & Kovalevska , I. V. . (2021). THE INFLUENCE OF ANTIDIABETIC COMBINED MEDICINAL PRODUCT GLIK VERIN BASED ON VOGLIBOSE AND QUERCETIN ON LIPID E XCHANGE INDICES UNDER CONDITIONS OF EXPERIMENTAL METABOLIC SYNDROME. Problems of Endocrine Pathology, 74(4), 124-130. https://doi.org/10.21856/j-PEP.2020.4.16